| 08/04/24 | 07:00:08 | 8 Apr 2024 | | Appointment of Chief Executive Officer |
| 05/04/24 | 12:00:00 | 5 Apr 2024 | | Results of the Annual General Meeting |
| 04/04/24 | 07:00:10 | 4 Apr 2024 | | Announcement of Placing |
| 28/03/24 | 07:00:10 | 28 Mar 2024 | | Issue of Warrants to IPF Funding Update |
| 26/03/24 | 10:00:00 | 26 Mar 2024 | | Faron´s Annual Report 2023 |
| 18/03/24 | 07:00:07 | 18 Mar 2024 | | Additional Positive Data from Phase 1 of BEXMAB |
| 14/03/24 | 07:00:11 | 14 Mar 2024 | | Faron to Host BEXMAB Webcast |
| 13/03/24 | 14:00:00 | 13 Mar 2024 | | Notice of Annual General Meeting 2024 |
| 13/03/24 | 07:00:05 | 13 Mar 2024 | | Financial Statement January 1 to December 31 2023 |
| 04/03/24 | 07:00:07 | 4 Mar 2024 | | Binding commitments for convertible loans |
| 28/02/24 | 16:00:00 | 28 Feb 2024 | | Replacement - Update to 2024 Financial Calendar |
| 27/02/24 | 18:00:00 | 27 Feb 2024 | | Update to Faron’s Financial Calendar for 2024 |
| 21/02/24 | 14:00:00 | 21 Feb 2024 | | Continued Negotiations Regarding Events of Default |
| 19/02/24 | 10:30:00 | 19 Feb 2024 | | Events of Default |
| 31/01/24 | 07:00:09 | 31 Jan 2024 | | Further re: Exercise of options |
| 25/01/24 | 07:00:07 | 25 Jan 2024 | | BEXMAB Insights into Patient Profiles |
| 19/01/24 | 13:00:00 | 19 Jan 2024 | | Exercise of options - Issue of equity |
| 09/01/24 | 07:00:02 | 9 Jan 2024 | | First Patient Dosed in Ph 2 of the BEXMAB Trial |
| 03/01/24 | 07:00:06 | 3 Jan 2024 | | Presentation at J.P. Morgan Healthcare Conference |
| 22/12/23 | 07:00:03 | 22 Dec 2023 | | Faron’s Financial Calendar for 2024 |
| 11/12/23 | 07:00:09 | 11 Dec 2023 | | Phase 1 BEXMAB data presented at ASH |
| 07/12/23 | 07:00:20 | 7 Dec 2023 | | MATINS Trial in Cell Reports Medicine |
| 04/12/23 | 07:00:06 | 4 Dec 2023 | | Grant of options |
| 06/11/23 | 08:13:21 | 6 Nov 2023 | | Faron Initiates Phase 2 Part of BEXMAB Study |
| 06/11/23 | 07:00:13 | 6 Nov 2023 | | Faron Initiates Phase 2 Part of BEXMAB Study |
| 02/11/23 | 13:00:01 | 2 Nov 2023 | | Faron to present data from BEXMAB study at ASH |
| 27/10/23 | 13:00:01 | 27 Oct 2023 | | Manager's transactions |
| 27/10/23 | 07:15:01 | 27 Oct 2023 | | Exercise of options |
| 27/10/23 | 07:00:09 | 27 Oct 2023 | | Results of Placing |
| 26/10/23 | 16:30:00 | 26 Oct 2023 | | Proposed Issue and Placing |
| 11/10/23 | 07:00:10 | 11 Oct 2023 | | Faron Announces Positive BEXMAB Study Update |
| 03/10/23 | 07:00:09 | 3 Oct 2023 | | Faron to host webcast on new BEXMAB study data |
| 22/09/23 | 16:00:00 | 22 Sept 2023 | | Board Changes |
| 22/09/23 | 11:00:02 | 22 Sept 2023 | | Results of EGM |
| 21/09/23 | 07:00:02 | 21 Sept 2023 | | Faron Appoints Interim Chief Medical Officer |
| 08/09/23 | 07:00:04 | 8 Sept 2023 | | Change in the Board of Directors |
| 06/09/23 | 07:00:06 | 6 Sept 2023 | | Faron to Present at H.C. Wainwright Conference |
| 01/09/23 | 10:00:04 | 1 Sept 2023 | | Notice of EGM |
| 31/08/23 | 14:00:01 | 31 Aug 2023 | | Exercise of options |
| 29/08/23 | 07:01:02 | 29 Aug 2023 | | Faron 2023 Half-Year Financial Results |
| 29/08/23 | 07:00:07 | 29 Aug 2023 | | FDA Orphan Drug Designation for Bexmarilimab |
| 04/08/23 | 07:00:07 | 4 Aug 2023 | | Notice of Half-Year Financial Results |
| 02/08/23 | 07:00:07 | 2 Aug 2023 | | Faron to Participate at Canaccord Conference |
| 25/07/23 | 07:00:12 | 25 Jul 2023 | | Grant of Options |
| 19/07/23 | 07:01:02 | 19 Jul 2023 | | Faron to Hold BEXMAB Study Conference Call |
| 19/07/23 | 07:00:03 | 19 Jul 2023 | | BEXMAB study update |
| 30/06/23 | 16:52:52 | 30 Jun 2023 | | Holding(s) in Company |
| 29/06/23 | 07:00:05 | 29 Jun 2023 | | Announcement of Placing |
| 12/06/23 | 07:00:05 | 12 Jun 2023 | | Exercise of options |
| 09/06/23 | 08:00:02 | 9 Jun 2023 | | New biomarker data from BEXMAB study at EHA2023 |
